Connect
MJA
MJA

National guidelines for the management of absolute cardiovascular disease risk

Christopher J O’Callaghan, Pei Rong and Min Y Goh
Med J Aust 2014; 200 (8): 454-456. || doi: 10.5694/mja13.11162
Published online: 1 May 2014

To the Editor: Concerns have been raised that the national Guidelines for the management of absolute cardiovascular disease risk1 recommend combining an angiotensin-converting enzyme (ACE) inhibitor with an angiotensin receptor blocker (ARB) for blood pressure reduction.2 Grenfell replied on behalf of the National Vascular Disease Prevention Alliance, stating that these agents are of the same pharmacological class3 and that the guidelines recommend using an agent from a different pharmacological class for second-line therapy. Therefore, he argued that the guidelines recommend “against prescribing” these agents in combination.3 This is incorrect.

  • Christopher J O’Callaghan
  • Pei Rong
  • Min Y Goh

  • Austin Health, Melbourne, VIC.


Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.